Corindus Announces Opening of First International Robotic Training Center

VERITAS Vision System Is Introduced by Johnson & Johnson

The company will offer live demos of the new system in a wet lab at the Johnson & Johnson booth (#2813) this weekend at the 2021 American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators Annual Meeting.

GenesisCare Orders 27 Elekta Flexitron Treatment Devices

"GenesisCare continues to demonstrate its commitment to improving patient outcomes worldwide and Elekta is delighted to play a vital partnering role to achieve this mission," said Gustaf Salford, Elekta's President and CEO.

FoodMarble AIRE Shown to Exceed the Performance of ‘Gold Standard’ SIBO Testing in Clinical Trial

SIBO is a very common disorder where there are excessive bacteria present in the small intestine. The true prevalence of SIBO in the general population is largely unknown, with some studies estimating its occurrence in up to 15% of healthy individuals. It is also largely associated with many other common clinical conditions, including irritable bowel syndrome, where 40-80% of IBS patients have SIBO.

Corindus Vascular Robotics, Inc. announced today the opening of the first international CorPath GRX Robotic Center in Tokyo, Japan. Earlier this year, Corindus partnered with Japan Medicalnext Co., Ltd., a wholly-owned entity of MC Healthcare, Inc. (subsidiary of Mitsubishi Corporation), to become the exclusive distributor of Corindus products in Japan, bringing robotic-assisted percutaneous coronary interventions (PCI) to the Japanese market. The first three CorPath GRX Systems were shipped to Japan Medicalnext by July and will be used at its newly constructed robotic center according to Japan’s regulation.

Tal Wenderow, Co-Founder and Executive Vice President of International and Business Development of Corindus said, “The opening of the first international robotic center represents an important milestone in the process of bringing precision vascular robotics to patients and physicians in Japan, and around the world.  He added, “Japan is the third largest PCI market with approximately 250,000 annual procedures, and is an important market as we grow our business internationally. We look forward to introducing our technology to the Japanese cardiology community.”

The company states that the robotic center and robotic simulation lab will be used to educate interventional cardiologists on the benefits of robotic-assisted PCI procedures. CorPath GRX is the second generation robotic-assisted PCI technology offering enhancements to the platform by adding important key upgrades that increase precision, improve workflow, and extend the capabilities and range of procedures that can be performed robotically.

“Robotic-assisted PCI is a natural extension of our current capabilities and will fit well within our current practice,” said Takafumi Ueno, MD, PhD, Director of Interventional Cardiology, Center of Cardiovascular Disease, Kurume University Hospital. “I look forward to seeing the positive impact the CorPath GRX System will have on patients and physicians.”

In preparation for commercial launch of CorPath GRX in Japan, the Company is working with Japan Medicalnext to secure Pharmaceutical and Medical Device Agency (PMDA) approval.

spot_img

DON'T MISS

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.